Production (Stage)
Hemostemix Inc.
HMTXF
$0.0836
-$0.0081-8.83%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.94% | -3.50% | -8.27% | -17.21% | -42.31% |
| Depreciation & Amortization | -- | -- | -100.00% | -100.00% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.26% | -19.69% | -42.98% | -50.53% | -58.36% |
| Operating Income | -61.26% | 19.69% | 42.98% | 50.53% | 58.36% |
| Income Before Tax | -93.70% | -2.51% | 26.05% | 40.83% | 62.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -93.70% | -2.51% | 37.39% | 48.49% | 65.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.70% | -2.51% | 37.39% | 48.49% | 65.88% |
| EBIT | -61.26% | 19.69% | 42.98% | 50.53% | 58.36% |
| EBITDA | -61.28% | 19.68% | 42.97% | 50.52% | 58.36% |
| EPS Basic | -73.57% | 15.63% | 42.91% | 53.94% | 70.71% |
| Normalized Basic EPS | -44.23% | 24.68% | 10.00% | 30.86% | 53.57% |
| EPS Diluted | -73.57% | 15.63% | 42.91% | 53.94% | 70.71% |
| Normalized Diluted EPS | -44.23% | 24.68% | 10.00% | 30.86% | 53.57% |
| Average Basic Shares Outstanding | 10.41% | 11.76% | 8.25% | 11.09% | 13.00% |
| Average Diluted Shares Outstanding | 10.41% | 11.76% | 8.25% | 11.09% | 13.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |